ACAD ACADIA PHARMACEUTICALS INC revenue, earnings and financials
For the quarter ended June 30, 2026, ACADIA PHARMACEUTICALS INC reported revenue of $308M (up 16.4% from a year earlier), net income of $31.5M and diluted EPS of $0.18; over the last four quarters revenue was $1.14B and net income $380M; for the fiscal year ended December 2025 revenue was $1.07B, up 11.9% on the year before.
ACAD annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $1.07B, gross profit n/a, operating income $105M, net income $391M (margin 36.5%), EPS $2.30
- Fiscal year ended Dec 2024: revenue $958M, gross profit n/a, operating income $231M, net income $226M (margin 23.6%), EPS $1.36
- Fiscal year ended Dec 2023: revenue $726M, gross profit $685M, operating income −$73.4M, net income −$61.0M (margin -8.4%), EPS −$0.37
- Fiscal year ended Dec 2022: revenue $517M, gross profit $507M, operating income −$224M, net income −$214M (margin -41.4%), EPS −$1.34
- Fiscal year ended Dec 2021: revenue $484M, gross profit $473M, operating income −$170M, net income −$168M (margin -34.7%), EPS −$1.05
ACAD quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $308M (up 16.4% year over year), net income $31.5M, EPS $0.18
- Quarter ended Mar 31, 2026: revenue $268M (up 9.7% year over year), net income $3.64M, EPS $0.02
- Quarter ended Dec 31, 2025 (from the annual report): revenue $284M (up 9.4% year over year), net income $274M, EPS $1.61
- Quarter ended Sep 30, 2025: revenue $279M (up 11.3% year over year), net income $71.8M, EPS $0.42
- Quarter ended Jun 30, 2025: revenue $265M (up 9.3% year over year), net income $26.7M, EPS $0.16
- Quarter ended Mar 31, 2025: revenue $244M (up 18.7% year over year), net income $19.0M, EPS $0.11
- Quarter ended Dec 31, 2024 (from the annual report): revenue $260M (up 12.4% year over year), net income $143M, EPS $0.86
- Quarter ended Sep 30, 2024: revenue $250M (up 18.3% year over year), net income $32.8M, EPS $0.20
- Quarter ended Jun 30, 2024: revenue $242M (up 46.4% year over year), net income $33.4M, EPS $0.20
- Quarter ended Mar 31, 2024: revenue $206M (up 73.8% year over year), net income $16.6M, EPS $0.10
- Quarter ended Dec 31, 2023: revenue $231M (up 69.3% year over year), net income $45.8M, EPS $0.28
- Quarter ended Sep 30, 2023: revenue $212M (up 62.0% year over year), net income −$65.2M, EPS −$0.40
- Quarter ended Jun 30, 2023: revenue $165M (up 22.8% year over year), net income $1.11M, EPS $0.01
- Quarter ended Mar 31, 2023: revenue $118M (up 2.6% year over year), net income −$43.0M, EPS −$0.27
- Quarter ended Dec 31, 2022: revenue $136M (up 4.4% year over year), net income −$41.7M, EPS −$0.26
- Quarter ended Sep 30, 2022: revenue $131M (down 0.7% year over year), net income −$27.2M, EPS −$0.17
- Quarter ended Jun 30, 2022: revenue $135M (up 16.8% year over year), net income −$34.0M, EPS −$0.21
- Quarter ended Mar 31, 2022: revenue $115M (up 8.4% year over year), net income −$113M, EPS −$0.70
- Quarter ended Dec 31, 2021: revenue $131M, net income −$43.1M, EPS −$0.27
- Quarter ended Sep 30, 2021: revenue $132M, net income −$14.5M, EPS −$0.09
ACAD cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow $110M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow $158M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow $16.7M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$114M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$126M, share buybacks n/a
ACAD balance sheet
- Jun 30, 2026: cash $385M, total assets $1.74B, total liabilities $436M, shareholders' equity $1.31B
- Mar 31, 2026: cash $282M, total assets $1.61B, total liabilities $357M, shareholders' equity $1.25B
- Dec 31, 2025: cash $178M, total assets $1.56B, total liabilities $337M, shareholders' equity $1.23B
- Sep 30, 2025: cash $258M, total assets $1.33B, total liabilities $413M, shareholders' equity $917M
- Jun 30, 2025: cash $254M, total assets $1.23B, total liabilities $403M, shareholders' equity $822M
- Mar 31, 2025: cash $218M, total assets $1.13B, total liabilities $367M, shareholders' equity $765M
- Dec 31, 2024: cash $320M, total assets $1.19B, total liabilities $455M, shareholders' equity $733M
- Sep 30, 2024: cash $155M, total assets $977M, total liabilities $400M, shareholders' equity $577M
What is ACAD's revenue?
ACADIA PHARMACEUTICALS INC reported $1.14B of revenue over its last four quarters, through June 30, 2026.
Is ACAD profitable?
Yes. ACADIA PHARMACEUTICALS INC earned $380M over the last four quarters.
What is ACAD's EPS?
Diluted earnings per share over the last four quarters were $2.23; $0.18 in the latest quarter.